Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice (Q41033867)

25 September 2017

title

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice (English)

1 reference

25 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ahmed Atef Mesalam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Patrick Mcclure

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jonathan Ball

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Thomas Pietschmann

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Philip Meuleman

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

11

Thomas Baumert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Koen Vercauteren

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Juliane Doerrbecker

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sabin Bhuju

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Robert Geffers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Naomi Van Den Eede

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Fulvia Troise

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lieven Verhoye

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ali Farhoudi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Riccardo Cortese

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Alfredo Nicosia

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Geert Leroux-Roels

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

25 August 2015

1 reference

25 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

2029-2034

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26306759%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and natural history of HCV infection.

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Curing chronic hepatitis C--the arc of a medical triumph

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Animal models for the study of HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

HCV animal models and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Rapid emergence of protease inhibitor resistance in hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Broadly neutralizing antibodies abrogate established hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Targeting HCV entry for development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Entry inhibitors and their use in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-309045